[ARRY] Array BioPharma Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 8.8 Change: 0.19 (2.21%)
Ext. hours: Change: 0 (0%)

chart ARRY

Refresh chart

Strongest Trends Summary For ARRY

ARRY is in the medium-term up 106% in 4 months and up 192% above S&P in 1 year. In the long-term up 957% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. Its proprietary clinical programs in Phase II clinical trial include ARRY-797, a p38 program for Lamin A/C-related dilated cardiomyopathy; and ARRY-502, a CRTh2 antagonist to treat Th2-driven allergic disease. The company?s proprietary programs also comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; and ARRY-614, a p38/Tie2 dual inhibitor for myelodysplastic syndromes. Its partnered clinical programs include various drug candidates, including Binimetinib, an MEK inhibitor for cancer; Selumetinib, an MEK inhibitor for cancer; ASLAN001/ARRY-543, an HER2/EGFR inhibitor for gastric cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; VTX-2337, a toll-like receptor for cancer; and Danoprevir, a Hepatitis C virus protease inhibitor. The company?s partnered clinical program

Fundamental Ratios
Shares Outstanding EPS-0.71 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 9.82% Sales Growth - Q/Q-75.48% P/E-10.59
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-2.94% ROE-12.23% ROI-3.87%
Current Ratio4.38 Quick Ratio Long Term Debt/Equity0.71 Debt Ratio0.9
Gross Margin-7.14% Operating Margin-5.45% Net Profit Margin-13.45% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities38.85 M Cash From Investing Activities12.56 M Cash From Operating Activities21.47 M Gross Profit-5.54 M
Net Profit58.31 M Operating Profit54.47 M Total Assets208.44 M Total Current Assets196.59 M
Total Current Liabilities44.92 M Total Debt107.98 M Total Liabilities158.29 M Total Revenue6.6 M
Technical Data
High 52 week24.85 Low 52 week12.92 Last close21.86 Last change0.14%
RSI40.1 Average true range0.88 Beta1.32 Volume2.74 M
Simple moving average 20 days-2.41% Simple moving average 50 days-5.74% Simple moving average 200 days20.64%
Performance Data
Performance Week0.28% Performance Month-2.19% Performance Quart-5.49% Performance Half48.61%
Performance Year40.58% Performance Year-to-date53.4% Volatility daily2.13% Volatility weekly4.77%
Volatility monthly9.78% Volatility yearly33.87% Relative Volume178.42% Average Volume2.54 M
New High0.46% New Low

News

2019-07-31 05:01:52 | Here’s How Pfizer Stock and Pharma Stand to Benefit From Mylan Deal

2019-07-29 11:40:59 | Pfizer PFE Beats on Q2 Earnings, to Merge Upjohn With Mylan

2019-07-29 10:12:02 | What's in Store for Array BioPharma ARRY in Q4 Earnings?

2019-07-29 08:56:00 | Pfizer stock down after revenue miss, merger announcement

2019-07-26 12:06:04 | What's in the Cards for Pfizer PFE This Earnings Season?

2019-07-26 09:55:00 | Array Acquisition Could Be a Huge Win for Pfizer, Analyst Says

2019-07-25 09:00:01 | Array BioPharma ARRY Moves to Buy: Rationale Behind the Upgrade

2019-07-10 10:35:00 | Rigrodsky & Long, P.A. Files Class Action Suit Against Array BioPharma Inc.

2019-07-10 09:25:00 | Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019

2019-07-10 08:19:00 | Here's Why Array BioPharma Soared 75.4% in June

2019-07-08 22:18:09 | Legal Investigation Alert: Halper Sadeh LLP Continues Investigating Whether the Sale of Array BioPharma Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ARRY

2019-07-08 11:43:00 | Pfizer Looks Pretty Smart With Array BioPharma Purchase. Here’s Why.

2019-07-06 05:19:00 | Array BioPharma Announces Interim Analysis Results from the BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

2019-07-02 15:38:28 | 3 Dow Jones Stocks to Buy for the Second Half

2019-06-28 11:05:03 | Should First Trust Mid Cap Growth AlphaDEX Fund FNY Be on Your Investing Radar?

2019-06-27 12:01:00 | Lifshitz & Miller LLP Announces Investigation of Array BioPharma Inc., C&J Energy Services, Inc., Liberty Expedia Holdings, Inc., and Raytheon Company, Shutterfly, Inc., Sotheby's and Stewardship Financial Corporation, and Zimmer Biomet Holdings, Inc.

2019-06-27 11:01:07 | ARRY, RTN, DATA and MDSO SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

2019-06-25 10:32:02 | Abbvie Decides to Acquire Allergan

2019-06-25 10:14:02 | AbbVie to Buy Botox-Maker Allergan, Look Ahead to G-20

2019-06-25 08:00:00 | Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

2019-06-24 16:23:08 | Why These Innovative Biotech ETFs Soaring

2019-06-24 14:00:00 | CJ, ARRY, BID INVESTOR ALERT: Halper Sadeh LLP Continues To Investigate Whether The Sale Of These Companies Is Fair To Shareholders - CJ, ARRY, BID

2019-06-24 11:45:24 | Eldorado to Buy Caesars

2019-06-24 10:06:02 | U.S. Senate Takes on Big Tech, Plus "Merger Monday"

2019-06-23 09:00:00 | These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

2019-06-21 20:00:00 | URGENT ALERT: Monteverde & Associates PC Launches an Investigation Regarding the Following Merger

2019-06-21 16:13:20 | Stock Market Rally Soars On Fed, China Trade Hopes; Facebook Cryptocurrency, Boeing 737 Max Order, Adobe, Oracle Earnings

2019-06-21 15:12:00 | Oh, By the Way, This Clinical Trial Didn't Work

2019-06-21 10:01:02 | 3 Big Biotechs Hold Growth Potential in Second Half of 2019

2019-06-21 09:40:01 | Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

2019-06-20 10:38:59 | Is Pfizer Overpaying for Array Biopharma?

2019-06-19 16:49:14 | Here's Pfizer's Motivation Behind Its Biggest Takeover In 3 Years

2019-06-19 11:20:03 | Cancer/Gene Therapy Biotechs in Focus After Pfizer-Array Deal

2019-06-19 09:27:36 | A Beloved Biotech ETF Could Lure Traders Again

2019-06-19 09:06:01 | Big Drugmakers That May Tread the M&A Path After Pfizer

2019-06-18 17:57:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Array BioPharma Acquisition

2019-06-18 15:51:00 | Papa John’s Auditor Swap Is Not a Good Look

2019-06-18 09:55:01 | Pfizer-Array Biopharma Deal Bump Up Biotech ETFs

2019-06-18 09:51:14 | Cancer Therapy Stocks Soar After Pfizer Deal

2019-06-18 09:51:01 | Pfizer to Buy Array BioPharma, Broaden Cancer Portfolio

2019-06-18 09:35:01 | Company News For Jun 18, 2019

2019-06-18 08:04:37 | See what the IHS Markit Score report has to say about Array Biopharma Inc.

2019-06-18 02:07:40 | PRESS DIGEST - Wall Street Journal - June 18

2019-06-17 18:14:10 | Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Array BioPharma Inc. NASDAQ: ARRY on Behalf of Array Shareholders and Encourages Array Investors to Contact the Firm

2019-06-17 17:06:21 | What Happened in the Stock Market Today

2019-06-17 17:00:00 | Why Pfizer's Acquisition of Array BioPharma Won't Pay Off Anytime Soon

2019-06-17 16:48:37 | How Pfizer's $11.4 Billion Takeover Of Array Signals More Mergers

2019-06-17 16:41:29 | Dow Jones Today: Almost a Case of the Mondays

2019-06-17 16:23:03 | Pfizer acquires Array in 2nd major Boulder bioscience merger this month

2019-06-17 16:05:26 | 5 Top Stock Trades for Tuesday: FB, NFLX, GILD, TSLA